Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor.

Area of Science:

• Oncology
• Immunotherapy
• Nanotechnology

Background:

• Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized hematologic malignancy treatment.
• Translating CAR T-cell success to solid tumors faces challenges including antigen scarcity and immunosuppressive tumor microenvironments.

Purpose of the Study:

• To review advancements in CAR T-cell therapy for solid tumors.
• To highlight nanotechnology-based strategies for overcoming therapeutic resistance.

Main Methods:

• Systematic review of CAR T-cell components and generations.
• Summary of recent innovations in nano-based CAR T-cell delivery and modulation.
• Exploration of mRNA, hydrogel, photothermal, and tumor microenvironment-based approaches.

Main Results:

• Nanotechnology offers solutions to key challenges in solid tumor CAR T-cell therapy.
• Innovations include improved CAR T-cell delivery and modulation of the tumor microenvironment.
• In vivo generation of CAR T cells is facilitated by these nanotechnologies.

Conclusions:

• Nano-based CAR T-cell therapy presents a promising platform for treating solid tumors.
• These strategies hold potential for treating other diseases beyond cancer.